These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18373192)

  • 1. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Breast Cancer Res Treat; 2009 Mar; 114(1):39-45. PubMed ID: 18373192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
    Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
    Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
    Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA; Gudlaugsson E;
    Eur J Cancer; 2007 Feb; 43(3):527-35. PubMed ID: 17110097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
    Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
    J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers.
    Baak JP; Colpaert CG; van Diest PJ; Janssen E; van Diermen B; Albernaz E; Vermeulen PB; Van Marck EA
    Eur J Cancer; 2005 Sep; 41(14):2093-101. PubMed ID: 16153819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
    Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
    J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
    Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.
    Skaland I; van Diest PJ; Janssen EA; Gudlaugsson E; Baak JP
    Hum Pathol; 2008 Apr; 39(4):584-90. PubMed ID: 18291440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Gonullu D; Alagol H
    Singapore Med J; 2008 Nov; 49(11):904-11. PubMed ID: 19037557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
    Kim YS; Kim JH; Yoon SM; Choi EK; Ahn SD; Lee SW; Kim JC; Yu CS; Kim HC; Kim TW; Chang HM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):796-802. PubMed ID: 19289261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.
    Rosenberg R; Friederichs J; Schuster T; Gertler R; Maak M; Becker K; Grebner A; Ulm K; Höfler H; Nekarda H; Siewert JR
    Ann Surg; 2008 Dec; 248(6):968-78. PubMed ID: 19092341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.
    Baak JP; Gudlaugsson E; Skaland I; Guo LH; Klos J; Lende TH; Søiland H; Janssen EA; Zur Hausen A
    Breast Cancer Res Treat; 2009 May; 115(2):241-54. PubMed ID: 18665447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
    Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
    Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
    Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
    Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.